title: Engagement of human monocyte-derived dendritic cells into interleukin (IL)-12 producers by IL-1beta + interferon (IFN)-gamma.
abstract: Dendritic cells (DCs) are potent antigen-presenting cells and can induce tumour- or pathogen-specific T cell responses. For adoptive immunotherapy purposes, immature DCs can be generated from adherent monocytes using granulocyte macrophage colony stimulating factor (GM-CSF) and interleukin (IL)-4, and further maturation is usually achieved by incubation with tumour necrosis factor (TNF)-alpha. However, TNF-alpha-stimulated DCs produce low levels of IL-12. In this study, we compared the effects of TNF-alpha, interferon (IFN)-gamma, IL-1beta or IFN-gamma + IL-1beta on the phenotypic and functional maturation of DCs. Our results show that IFN-gamma, but not IL-1beta, augmented the surface expression of CD80, CD83 and CD86 molecules without inducing IL-12 production from DCs. However, IL-1beta, but not IFN-gamma, induced IL-12 p40 production by DCs without enhancing phenotypic maturation. When combined, IFN-gamma + IL-1beta treatment profoundly up-regulated the expression of CD80, CD83, CD86 and major histocompatibility complex (MHC) class II antigens. Furthermore, IFN-gamma + IL-1beta-treated DCs produced larger amounts of IL-12 and induced stronger T cell proliferation and IFN-gamma secretion in primary allogeneic mixed lymphocyte reaction (MLR) than did TNF-alpha-treated DCs. Our results show that IFN-gamma + IL-1beta induced human monocyte-derived DCs to differentiate into Th1-prone mature DCs.
authors.affiliation: Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. nakahara@dermatol.med.kyushu-u.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Nakahara
authors.forename: K
authors.initials: K
authors.lastname: Urabe
authors.forename: S
authors.initials: S
authors.lastname: Fukagawa
authors.forename: H
authors.initials: H
authors.lastname: Uchi
authors.forename: K
authors.initials: K
authors.lastname: Inaba
authors.forename: M
authors.initials: M
authors.lastname: Furue
authors.forename: Y
authors.initials: Y
authors.lastname: Moroi
mesh_terms: D018929:Cell Culture Techniques; D002454:Cell Differentiation / Q000187:drug effects; D003713:Dendritic Cells / Q000276:immunology* / Q000637:transplantation; D005434:Flow Cytometry; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007371:Interferon-gamma / Q000494:pharmacology*; D007375:Interleukin-1 / Q000494:pharmacology*; D016753:Interleukin-10 / Q000096:biosynthesis; D018664:Interleukin-12 / Q000096:biosynthesis*; D007959:Lymphocyte Culture Test, Mixed; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D014184:Transplantation, Homologous; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D018664:Interleukin-12; D007371:Interferon-gamma
references.citation: FASEB J. 1999 Nov;13(14):2021-30
references.pmid: 10544185
references.citation: Immunity. 1998 Mar;8(3):275-83
references.pmid: 9529145
references.citation: Annu Rev Immunol. 2000;18:245-73
references.pmid: 10837059
references.citation: J Immunother. 2000 Jul-Aug;23(4):487-98
references.pmid: 10916759
references.citation: J Immunol. 2000 Sep 15;165(6):3492-6
references.pmid: 10975870
references.citation: Blood. 2000 Nov 15;96(10):3499-504
references.pmid: 11071647
references.citation: Int Immunol. 2001 Aug;13(8):1053-61
references.pmid: 11470775
references.citation: Adv Immunol. 2001;79:55-92
references.pmid: 11680011
references.citation: J Allergy Clin Immunol. 2002 Aug;110(2):269-76
references.pmid: 12170268
references.citation: Nat Rev Immunol. 2003 Feb;3(2):133-46
references.pmid: 12563297
references.citation: J Exp Med. 1989 Sep 1;170(3):827-45
references.pmid: 2504877
references.citation: J Immunol. 1991 May 1;146(9):3074-81
references.pmid: 1673147
references.citation: Annu Rev Immunol. 1991;9:271-96
references.pmid: 1910679
references.citation: J Exp Med. 1998 Jul 20;188(2):373-86
references.pmid: 9670049
references.citation: J Immunol. 1998 Aug 1;161(3):1083-6
references.pmid: 9686565
references.citation: J Immunol. 1998 Aug 15;161(4):1947-53
references.pmid: 9712065
references.citation: Eur J Immunol. 1998 Sep;28(9):2760-9
references.pmid: 9754563
references.citation: Adv Immunol. 1998;70:83-243
references.pmid: 9755338
references.citation: Science. 1999 Feb 19;283(5405):1183-6
references.pmid: 10024247
references.citation: Blood. 1999 Mar 1;93(5):1634-42
references.pmid: 10029592
references.citation: J Immunol. 1999 Mar 1;162(5):2472-5
references.pmid: 10072485
references.citation: J Exp Med. 1992 Nov 1;176(5):1387-98
references.pmid: 1357073
references.citation: J Immunol. 1993 Sep 1;151(5):2390-8
references.pmid: 8103065
references.citation: J Exp Med. 1994 Apr 1;179(4):1109-18
references.pmid: 8145033
references.citation: J Exp Med. 1994 Apr 1;179(4):1397-402
references.pmid: 8145053
references.citation: Eur J Immunol. 1994 Apr;24(4):793-8
references.pmid: 7908633
references.citation: J Immunol. 1995 Jan 1;154(1):116-27
references.pmid: 7527811
references.citation: Eur J Immunol. 1995 Jan;25(1):200-6
references.pmid: 7843232
references.citation: Immunol Today. 1995 Mar;16(3):117-21
references.pmid: 7718082
references.citation: Immunol Today. 1995 Oct;16(10):500-1
references.pmid: 7576055
references.citation: J Exp Med. 1996 Aug 1;184(2):747-52
references.pmid: 8760829
references.citation: J Immunol Methods. 1996 Sep 27;196(2):121-35
references.pmid: 8841451
references.citation: J Immunol. 1997 Mar 15;158(6):2919-25
references.pmid: 9058830
references.citation: J Exp Med. 1997 Oct 20;186(8):1183-7
references.pmid: 9379142
references.citation: Nature. 1998 Mar 19;392(6673):245-52
references.pmid: 9521319
references.citation: J Exp Med. 1999 Dec 6;190(11):1669-78
references.pmid: 10587357